Published July 9, 2026
The Most Expensive Line on Every Cannabis P&L Just Changed — for Some of You
For forty years, Section 280E has been the silent partner that takes more than its share. The rule is brutally short: businesses trafficking in Schedule I or II controlled substances get no federal deductions and no credits. Not rent, payroll, marketing, insurance, or depreciation. Only cost of goods sold comes off the top, which means cannabis operators have been paying federal tax on something closer to gross profit than net income — with effective rates north of 70%, and in bad years north of 90%.
That math finally cracked this spring. When the Justice Department’s April 22 order moved FDA-approved cannabis products and state-licensed medical marijuana to Schedule III, it pulled those activities out of 280E’s reach. The next day, Treasury and the IRS confirmed guidance is coming — and the early signals are more generous than most operators expected.
Here’s what we actually know, what’s still unresolved, and what the smart money is doing right now.
The Good News: A Full-Year Pass
The headline detail from Treasury’s announcement is the transition rule. Rather than forcing businesses to split 2026 into pre- and post-rescheduling periods, the forthcoming guidance is expected to apply relief to the entire taxable year that includes the order’s effective date.
For calendar-year taxpayers, that means qualifying medical operators can treat 280E as gone from January 1, 2026 — not April 22. A full year of ordinary deductions: rent, wages, advertising, professional fees, the works. By IRS standards, that’s about as generous as transition rules get.
The dollars are not small. Industry modeling has put 280E’s cost at somewhere between $400,000 and $800,000-plus in extra tax liability per store per year, with the aggregate industry burden estimated around $2.3 billion annually. One analysis of higher-volume states pegged average savings at roughly $805,000 per store. For an industry where only about a quarter of operators turn an after-tax profit, this is the difference between bleeding and building.
The Catch: Medical Yes, Recreational No
Now the fine print, because it’s doing a lot of work.
The April order rescheduled exactly two categories: FDA-approved marijuana products and marijuana operating under a qualifying state medical license. Everything else — adult-use cannabis, unlicensed crops, bulk biomass not yet in a covered product — remains Schedule I. And 280E applies in full to Schedule I activity.
That leaves the industry’s largest segment, recreational, exactly where it was. It also creates a genuinely messy middle: the dispensary running medical and adult-use under one roof, or the vertically integrated operator selling into both channels. Treasury has flagged that its guidance will require apportioning shared expenses — rent, payroll, overhead — between the relieved medical side and the still-taxed recreational side. Until that guidance drops, mixed operators are doing allocation math on assumptions.
The recreational side’s fate rides on the DEA hearing happening right now in Arlington, which wraps by July 15. If full rescheduling goes through, 280E relief extends to the whole industry. Until then, this is a partial reset.
The Billion-Dollar Open Question: Retroactivity
Here’s where it gets genuinely interesting. The April order directs the IRS to consider retrospective relief — refunds for past years in which a business operated under a state medical license. Consider is not commit, and nothing has been decided.
The stakes are enormous. Under the standard statute of limitations, returns from roughly 2022 and 2023 are still open to amendment for most filers. Three camps have formed among tax advisors:
The aggressive play: file amended returns now claiming 280E relief for open years, and be ready to fight the IRS in Tax Court when the claims get denied. Expensive, uncertain, and slow.
The conservative play: wait for formal guidance and accept that closed years may stay closed.
The middle play — and the one most advisors are steering clients toward: file protective refund claims now. They’re cheap, well-established, and they freeze the statute-of-limitations clock on your open years without committing you to litigation. If the IRS grants retroactive relief, you’re in line. If it doesn’t, you’ve lost nothing.
Whichever route an operator takes, retroactivity is shaping up to be the most litigated cannabis tax question of the next two years. Document everything.
What Operators Should Be Doing This Quarter
The advisor consensus boils down to a short list. First, confirm you actually qualify — relief follows the activity, not the vibe; check that your products and licenses fall inside the order’s covered categories before booking a single new deduction. Second, get your allocation house in order if you run mixed operations, because clean books separating medical and adult-use activity will be worth real money when apportionment guidance lands. Third, revisit structure: entity choices, inventory costing, and capitalization methods that made sense as 280E workarounds may now be suboptimal — the C-corp-versus-passthrough math is starting to look like every other industry’s again. And fourth, talk to your CPA about protective claims before your open years start expiring.
One more wrinkle worth knowing: the rescheduling may even open the door for patients to deduct medical cannabis as a Section 213 medical expense — though that deduction requires an actual prescription, not just a recommendation, so its practical reach is narrow for now.
The Big Picture
Strip away the tax code citations and the story is simple: for the first time since 1982, a meaningful slice of the legal cannabis industry will be taxed like a normal business. The land-grab era ended with last year’s first-ever sales decline; the era that replaces it will be won by operators who convert this tax relief into margin, reinvestment, and staying power — and who positioned themselves before the guidance, not after.
The usual caveat applies double here: this is journalism, not tax advice. The guidance isn’t final, the details will matter enormously, and every operator’s facts differ. Get a cannabis-literate CPA in the room before you act on any of it.
But for an industry that’s spent four decades paying taxes on money it never kept — the direction of travel just changed.
Follow the Money
Tax rules, banking reform, market data, and the policies reshaping cannabis as a business — we break down what it all means for operators and investors.
👉 Visit our Cannabis Business hub for the latest industry news, analysis, and in-depth coverage from Marijuana.net.
Sources: